Potential role of odanacatib in the treatment of osteoporosis

References

• McClungMRBisphosphonatesEndocrinol Metab Clin North Am200332125327112699302
   PubMed Web of Science ®Google Scholar
• KhoslaSBurrDCauleyJAmerican Society for Bone and Mineral ResearchBisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res200722101479149117663640
   PubMed Web of Science ®Google Scholar
• ShaneEBurrDEbelingPRAmerican Society for Bone and Mineral ResearchAtypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res201025112267229420842676
   PubMed Web of Science ®Google Scholar
• VahleJLSatoMLongGGSkeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safetyToxicol Pathol200230331232112051548
   PubMed Web of Science ®Google Scholar
• BaronRHesseEUpdate on bone anabolics in osteoporosis treatment: rationale, current status, and perspectivesJ Clin Endocrinol Metab201297231132522238383
   PubMed Web of Science ®Google Scholar
• MartinTJSimsNANgKWRegulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosisOsteoporos Int20081981125113818338097
   PubMed Web of Science ®Google Scholar
• WalkerECMcGregorNEPoultonIJCardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodelingJ Bone Miner Res200823122025203218665789
   PubMed Web of Science ®Google Scholar
• PedersonLRuanMWestendorfJJKhoslaSOurslerMJRegulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphateProc Natl Acad Sci U S A200810552207642076919075223
   PubMed Web of Science ®Google Scholar
• Negishi-KogaTShinoharaMKomatsuNSuppression of bone formation by osteoclastic expression of semaphorin 4DNat Med201112111473148022019888
   PubMed Web of Science ®Google Scholar
• TangYWuXLeiWTGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formationNat Med200915775776519584867
   PubMed Web of Science ®Google Scholar
• BaronRFerrariSRussellRGDenosumab and bisphosphonates: different mechanisms of action and effectsBone201148467769221145999
   PubMed Web of Science ®Google Scholar
• ZhaoCIrieNTakadaYBidirectional ephrinB2-EphB4 signaling controls bone homeostasisCell Metab20064211112116890539
   PubMed Web of Science ®Google Scholar
• MartinTJAllanEHHoPWCommunication between ephrinB2 and EphB4 within the osteoblast lineageAdv Exp Med Biol2010658516019950015
   PubMed Web of Science ®Google Scholar
• SimsNAEPHs and ephrins: many pathways to regulate osteoblasts and osteoclastsBonekey Osteovision201079304313
   Google Scholar
• KhoslaSWestendorfJJOurslerMJBuilding bone to reverse osteoporosis and repair fracturesJ Clin Invest2008118242142818246192
   PubMed Web of Science ®Google Scholar
• CranneyAGuyattGGriffithLWellsGTugwellPRosenCOsteoporosis Methodology Group and The Osteoporosis Research Advisory GroupMeta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosisEndocr Rev200223457057812202472
   PubMed Web of Science ®Google Scholar
• RosenCJClinical practice. Postmenopausal osteoporosisN Engl J Med2005353659560316093468
   PubMed Web of Science ®Google Scholar
• RaiszLGPathogenesis of osteoporosis: concepts, conflicts, and prospectsJ Clin Invest2005115123318332516322775
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellRHORIZON Pivotal Fracture Trial Once-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• DelmasPDTreatment of postmenopausal osteoporosisLancet200235993222018202612076571
   PubMed Web of Science ®Google Scholar
• LewieckiEMNew targets for intervention in the treatment of post-menopausal osteoporosisNat Rev Rheumatol201171163163821931340
   PubMed Web of Science ®Google Scholar
• NeerRMArnaudCDZanchettaJREffect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med2001344191434144111346808
   PubMed Web of Science ®Google Scholar
• BauerDCGarneroPBilezikianJPShort-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosisJ Clin Endocrinol Metab20069141370137516449339
   PubMed Web of Science ®Google Scholar
• TolarJTeitelbaumSLOrchardPJOsteopetrosisN Engl J Med2004351272839284915625335
   PubMed Web of Science ®Google Scholar
• ZhaoHKitauraHSandsMSRossFPTeitelbaumSLNovackDVCritical role of beta3 integrin in experimental postmenopausal osteoporosisJ Bone Miner Res200520122116212316294265
   PubMed Web of Science ®Google Scholar
• MarziaMSimsNAVoitSDecreased c-Src expression enhances osteoblast differentiation and bone formationJ Cell Biol2000151231132011038178
   PubMed Web of Science ®Google Scholar
• SchallerSHenriksenKSørensenMGKarsdalMAThe role of chloride channels in osteoclasts: ClC-7 as a target for osteoporosis treatmentDrug News Perspect200518848949516391718
   PubMedGoogle Scholar
• BrockstedtHBollerslevJMelsenFMosekildeLCortical bone remodeling in autosomal dominant osteopetrosis: a study of two different phenotypesBone199618167728717539
   PubMed Web of Science ®Google Scholar
• Del FattoreAPeruzziBRucciNClinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatmentJ Med Genet200643431532516118345
   PubMed Web of Science ®Google Scholar
• ReiserJAdairBReinheckelTSpecialized roles for cysteine cathepsins in health and diseaseJ Clin Invest2010120103421343120921628
   PubMed Web of Science ®Google Scholar
• BrömmeDOkamotoKHuman cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distributionBiol Chem Hoppe Seyler199537663793847576232
   PubMed Web of Science ®Google Scholar
• GauthierJYChauretNCromlishWThe discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin KBioorg Med Chem Lett200818392392818226527
   PubMed Web of Science ®Google Scholar
• RodanSBDuongLTCathepsin K – a new molecular target for osteoporosisBonekey Osteovision2008511624
   Google Scholar
• YamazaTGotoTKamiyaTKobayashiYSakaiHTanakaTStudy of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femurBone19982364995099855458
   PubMed Web of Science ®Google Scholar
• VääräniemiJHalleenJMKaarlonenKIntracellular machinery for matrix degradation in bone-resorbing osteoclastsJ Bone Miner Res20041991432144015312243
   PubMed Web of Science ®Google Scholar
• XiaLKilbJWexHLocalization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfonesBiol Chem1999380667968710430032
   PubMed Web of Science ®Google Scholar
• GarneroPBorelOByrjalsenIThe collagenolytic activity of cathepsin K is unique among mammalian proteinasesJ Biol Chem19982734832347323529822715
   PubMed Web of Science ®Google Scholar
• FuruyamaNFujisawaYRegulation of collagenolytic cysteine protease synthesis by estrogen in osteoclastsSteroids200065737137810899536
   PubMed Web of Science ®Google Scholar
• TroenBRThe regulation of cathepsin K gene expressionAnn N Y Acad Sci2006106816517216831915
   PubMed Web of Science ®Google Scholar
• FujisakiKTanabeNSuzukiNReceptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cellsLife Sci200780141311131817306833
   PubMed Web of Science ®Google Scholar
• MaroteauxPLamyM2 cases of a condensing osseous disease: pycnodysostosisArch Fr Pediatr196219267274 French14470120
   PubMedGoogle Scholar
• GelbBDShiGPChapmanHADesnickRJPycnodysostosis, a lysosomal disease caused by cathepsin K deficiencyScience19962735279123612388703060
   PubMed Web of Science ®Google Scholar
• MotyckovaGFisherDEPycnodysostosis: role and regulation of cathepsin K in osteoclast function and human diseaseCurr Mol Med20022540742112125807
   PubMedGoogle Scholar
• NishiYAtleyLEyreDEDetermination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradationJ Bone Miner Res199914111902190810571690
   PubMed Web of Science ®Google Scholar
• SaftigPHunzikerEWehmeyerOImpaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient miceProc Natl Acad Sci U S A1998952313453134589811821
   PubMed Web of Science ®Google Scholar
• GowenMLaznerFDoddsRCathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralizationJ Bone Miner Res199914101654166310491212
   PubMed Web of Science ®Google Scholar
• ChenWYangSAbeYNovel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescenceHum Mol Genet200716441042317210673
   PubMed Web of Science ®Google Scholar
• PennypackerBSheaMLiuQBone density, strength, and formation in adult cathepsin K (−/−) miceBone200944219920718845279
   PubMed Web of Science ®Google Scholar
• KivirantaRMorkoJUusitaloHAroHTVuorioERantakokkoJAccelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin KJ Bone Miner Res20011681444145211499867
   PubMed Web of Science ®Google Scholar
• YamashitaDSDoddsRACathepsin K and the design of inhibitors of cathepsin KCurr Pharm Des20006112410637370
   PubMed Web of Science ®Google Scholar
• TavaresFXBoncekVDeatonDNDesign of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin kJ Med Chem200447358859914736240
   PubMed Web of Science ®Google Scholar
• BrömmeDLecailleFCathepsin K inhibitors for osteoporosis and potential off-target effectsExpert Opin Investig Drugs2009185585600
   PubMed Web of Science ®Google Scholar
• RussellRGWattsNBEbetinoFHRogersMJMechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacyOsteoporos Int200819673375918214569
   PubMed Web of Science ®Google Scholar
• FalgueyretJPDesmaraisSOballaRLysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivityJ Med Chem200548247535754316302795
   PubMed Web of Science ®Google Scholar
• BlackWCPercivalMDThe consequences of lysosomotropism on the design of selective cathepsin K inhibitorsChembiochem20067101525153516921579
   PubMed Web of Science ®Google Scholar
• DesmaraisSBlackWCOballaREffect of cathepsin k inhibitor basicity on in vivo off-target activitiesMol Pharmacol200873114715617940194
   PubMed Web of Science ®Google Scholar
• LiCSDeschenesDDesmaraisSIdentification of a potent and selective non-basic cathepsin K inhibitorBioorg Med Chem Lett20061671985198916413777
   PubMed Web of Science ®Google Scholar
• KimTSTaskerASNon-covalent cathepsin K inhibitors for the treatment of osteoporosisCurr Top Med Chem20066435536016611147
   PubMed Web of Science ®Google Scholar
• MarquisRWRuYLoCastroSMAzepanone-based inhibitors of human and rat cathepsin KJ Med Chem20014491380139511311061
   PubMed Web of Science ®Google Scholar
• PodgorskiIFuture of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?Future Med Chem200911213420126511
   PubMed Web of Science ®Google Scholar
• StochSAWagnerJACathepsin K inhibitors: a novel target for osteoporosis therapyClin Pharmacol Ther200883117217618073778
   PubMed Web of Science ®Google Scholar
• PalmerJTBryantCWangDXDesign and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin KJ Med Chem200548247520753416302794
   PubMed Web of Science ®Google Scholar
• KumarSDareLVasko-MoserJAA highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeysBone200740112213116962401
   PubMed Web of Science ®Google Scholar
• YamashitaDSMarquisRWXieRStructure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitorsJ Med Chem20064951597161216509577
   PubMed Web of Science ®Google Scholar
• StroupGJeromeCYamashitaDSKumarSHistomorphometric and biochemical evidence for a cortical bone-forming effect of a cathepsin K inhibitor in ovariectomized cynomolgus monkeysJ Bone Miner Res200520Suppl 1Abstract F236
   Google Scholar
• StroupGBDareLVasko-MoserJHoffmanSKumarSRepeat daily dosing with a high potent inhibitor of cathepsin K results in significant, transient elevation of plasma PTH in cynomolgus monkeysJ Bone Miner Res200621Suppl 1Abstract SA236
   Google Scholar
• BlackWCPeptidomimetic inhibitors of cathepsin KCurr Top Med Chem201010774575120337585
   PubMed Web of Science ®Google Scholar
• JeromeCMissbachMGamseRBalicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeysOsteoporos Int201122123001301121308366
   PubMed Web of Science ®Google Scholar
• AdamiSSupronikJHalaTEffect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosisJ Bone Miner Res200621Suppl 1Abstract S24
   Google Scholar
• PeroniAZiniABragaVColatoCAdamiSGirolomoniGDrug-induced morphea: report of a case induced by balicatib and review of the literatureJ Am Acad Dermatol200859112512918410981
   PubMed Web of Science ®Google Scholar
• YamadaHMoriNakanishiYOrally active cathepsin K inhibitor, ONO-5344, potently improved bone mineral density not only in trabecular bone but also in cortical bone in ovariectomized cynomolgus monkeysJ Bone Miner Res200924Suppl 1Abstract SA042
   Google Scholar
• YamadaHMoriHKunishigeAEfficacy of ONO-5344, a cathepsin K inhibitor, on bone mass and strength in ovariectomized cynomolgus monkeysJ Bone Miner Res201025Suppl 1Abstract SA0438
   Google Scholar
• EastellRNagaseSOhyamaMSafety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN studyJ Bone Miner Res20112661303131221312264
   PubMed Web of Science ®Google Scholar
• PennypackerBRodanSMasarachiaPRodanGKimmelDBBone effects of a cathepsin K inhibitor in the adult estrogen-deficient rabbitJ Bone Miner Res200621Suppl 1Abstract S383
   Google Scholar
• MasarachiaPJPennypackerBLPickarskiMOdanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeysJ Bone Miner Res201227350952322113859
   PubMed Web of Science ®Google Scholar
• CusickTChenCMPennypackerBLOdanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkeyJ Bone Miner Res201227352453722113921
   PubMed Web of Science ®Google Scholar
• AlataloSLIvaskaKKWaguespackSGEconsMJVäänänenHKHalleenJMOsteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis)Clin Chem200450588389015016726
   PubMed Web of Science ®Google Scholar
• HalleenJMTiitinenSLYlipahkalaHFagerlundKMVäänänenHKTartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorptionClin Lab2006529–1049950917078477
   PubMed Web of Science ®Google Scholar
• PennypackerBWuGKornRSamadfamRSmithSYDuongLTEfficacy of the combination of parathyroid hormone plus odanacatib or alendronate, as compared to the monotherapies in estrogen-deficient rabbitsJ Bone Miner Res201126Suppl 1Abstract 1030
   Google Scholar
• StochSAMillerDLVan DyckKEffect of cathepsin K inhibition on bone resorption markers in healthy postmenopausal womenJ Bone Miner Res200621Suppl 1Abstract 1224
   Google Scholar
• StochSAZajicSStoneJEffect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studiesClin Pharmacol Ther200986217518219421185
   PubMed Web of Science ®Google Scholar
• CostaAGCusanoNESilvaBCCremersSBilezikianJPCathepsin K: its skeletal actions and role as a therapeutic target in osteoporosisNat Rev Rheumatol20117844745621670768
   PubMed Web of Science ®Google Scholar
• HarrisSTGertzBJGenantHKThe effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal womenJ Clin Endocrinol Metab1993766139914068501142
   PubMed Web of Science ®Google Scholar
• SchnitzerTBoneHGCrepaldiGTherapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupAging (Milano)200012111210746426
   PubMedGoogle Scholar
• BoneHGMcClungMRRouxCOdanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone densityJ Bone Miner Res201025593794719874198
   PubMed Web of Science ®Google Scholar
• LewieckiEMOdanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodelingIDrugs2009121279980919943223
   PubMed Web of Science ®Google Scholar
• EismanJABoneHGHoskingDJOdanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effectJ Bone Miner Res201126224225120740685
   PubMed Web of Science ®Google Scholar
• NeeleSJEvertzRDe Valk-De RooGRoosJCNetelenbosJCEffect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal womenBone200230459960311934652
   PubMed Web of Science ®Google Scholar
• BoneHGBologneseMAYuenCKEffects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone massJ Clin Endocrinol Metab201196497298021289258
   PubMed Web of Science ®Google Scholar
• MillerPDBologneseMALewieckiEMEffect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trialBone200843222222918539106
   PubMed Web of Science ®Google Scholar
• GreyABollandMJWattieDHorneAGambleGReidIRThe anti-resorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal womenJ Clin Endocrinol Metab200994253854419050050
   PubMed Web of Science ®Google Scholar
• BinkleyNGilchristNLangdahlBTreatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trialJ Bone Mineral Res201126Suppl 1Abstract FR0453
   Google Scholar
• Littlewood-EvansAKokuboTIshibashiOLocalization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistryBone199720281869028530
   PubMed Web of Science ®Google Scholar
• InaokaTBilbeGIshibashiOTezukaKKumegawaMKokuboTMolecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in boneBiochem Biophys Res Commun1995206189967818555
   PubMed Web of Science ®Google Scholar
• BühlingFWaldburgNGerberACathepsin K expression in human lungAdv Exp Med Biol200047728128610849755
   PubMed Web of Science ®Google Scholar
• RüngerTMQuintanilla-DieckMJBhawanJRole of cathepsin K in the turnover of the dermal extracellular matrix during scar formationJ Invest Dermatol2007127229329716946716
   PubMed Web of Science ®Google Scholar
• HouWSLiZGordonRECathepsin K is a critical protease in synovial fibroblast-mediated collagen degradationAm J Pathol200115962167217711733367
   PubMed Web of Science ®Google Scholar
• Littlewood-EvansAJBilbeGBowlerWBThe osteoclast-associated protease cathepsin K is expressed in human breast carcinomaCancer Res19975723538653909393764
   PubMed Web of Science ®Google Scholar
• BrubakerKDVessellaRLTrueLDThomasRCoreyECathepsin K mRNA and protein expression in prostate cancer progressionJ Bone Miner Res200318222223012568399
   PubMed Web of Science ®Google Scholar
• EvertsVHouWSRiallandXCathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblastsCalcif Tissue Int200373438038612874701
   PubMed Web of Science ®Google Scholar
• BühlingFRöckenCBraschFPivotal role of cathepsin K in lung fibrosisAm J Pathol200416462203221615161653
   PubMed Web of Science ®Google Scholar
• SrivastavaMSteinwedeKKivirantaROverexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosisRespir Res200895418638383
   PubMed Web of Science ®Google Scholar
• Quintanilla-DieckMJCodrianskyKKeadyMBhawanJRüngerTMExpression and regulation of cathepsin K in skin fibroblastsExp Dermatol200918759660219469903
   PubMed Web of Science ®Google Scholar
• TepelCBrömmeDHerzogVBrixKCathepsin K in thyroid epithelial cells: sequence, localization and possible function in extracellular proteolysis of thyroglobulinJ Cell Sci2000113Pt 244487449811082042
   PubMed Web of Science ®Google Scholar
• FriedrichsBTepelCReinheckelTThyroid functions of mouse cathepsins B, K, and LJ Clin Invest2003111111733174512782676
   PubMed Web of Science ®Google Scholar
• DauthSSîrbulescuRFJordansSCathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficitsBMC Neurosci2011127421794126
   PubMed Web of Science ®Google Scholar
• LecailleFChowdhurySPurisimaEBrömmeDLalmanachGThe S2 subsites of cathepsins K and L and their contribution to collagen degradationProtein Sci200716466267017384231
   PubMed Web of Science ®Google Scholar
• IsabelEBatemanKPChauretNThe discovery of MK-0674, an orally bioavailable cathepsin K inhibitorBioorg Med Chem Lett201020388789220061146
   PubMed Web of Science ®Google Scholar
• RoodmanGDMechanisms of bone metastasisN Engl J Med2004350161655166415084698
   PubMed Web of Science ®Google Scholar
• EastellRBreast cancer and the risk of osteoporotic fracture: A paradoxJ Clin Endocrinol Metab2007921424317209223
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBSchippingerWABCSG-12 Trial Investigators, Marth CEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med2009360767969119213681
   PubMed Web of Science ®Google Scholar
• BrufskyAMBossermanLDCaradonnaRRZoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up resultsClin Breast Cancer200992778519433387
   PubMed Web of Science ®Google Scholar
• EllisGKBoneHGChlebowskiREffect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 studyBreast Cancer Res Treat20091181818719308727
   PubMed Web of Science ®Google Scholar
• SantenRJClinical review: Effect of endocrine therapies on bone in breast cancer patientsJ Clin Endocrinol Metab201196230831921147884
   PubMed Web of Science ®Google Scholar
• JensenABWynneCRamirezGThe cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trialClin Breast Cancer201010645245821147688
   PubMed Web of Science ®Google Scholar
• Salminen-MankonenHJMorkoJVuorioERole of cathepsin K in normal joints and in the development of arthritisCurr Drug Targets20078231532317305509
   PubMed Web of Science ®Google Scholar
• YasudaYKaletaJBrömmeDThe role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeuticsAdv Drug Deliv Rev200557797399315876399
   PubMed Web of Science ®Google Scholar
• MorkoJKivirantaRJoronenKSäämänenAMVuorioESalminen-MankonenHSpontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin KArthritis Rheum200552123713371716329095
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRFREEDOM TrialDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• BoneHGBologneseMAYuenCKEffects of denosumab on bone mineral density and bone turnover in postmenopausal womenJ Clin Endocrinol Metab20089362149215718381571
   PubMed Web of Science ®Google Scholar
• SosaMHernándezDSegarraMCGómezAde la PenaEBetancorPEffect of two forms of alendronate administration upon bone mass after two years of treatmentJ Clin Densitom200251273411940726
   PubMed Web of Science ®Google Scholar
• DuongLTTherapeutic inhibition of cathepsin K – reducing bone resorption while maintaining bone formationBonekey Reports2012110.1038/bonekey.2012.67.
   Google Scholar
• KhoslaSOdanacatib: location and timing are everythingJ Bone Miner Res201227350650822354850
   PubMed Web of Science ®Google Scholar
• BalenaRShihMSParfittAMBone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy womenJ Bone Miner Res1992712147514821481733
   PubMed Web of Science ®Google Scholar
• Fratzl-ZelmanNValentaARoschgerPDecreased bone turnover and deterioration of bone structure in two cases of pycnodysostosisJ Clin Endocrinol Metab20048941538154715070910
   PubMed Web of Science ®Google Scholar
• BauerDCDiscontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?J Bone Miner Res201126223924121254231
   PubMed Web of Science ®Google Scholar
• BlackDMGreenspanSLEnsrudKEPaTH Study InvestigatorsThe effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisN Engl J Med2003349131207121514500804
   PubMed Web of Science ®Google Scholar
• Merck A study of MK0822 in postmenopausal women with osteoporosis to assess fracture risk (MK-0822-018 AM4 EXT)ClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2007 [updated March 16, 2012]. Available from: clinicaltrials.gov/ct2/show/NCT0529373. NLM identifier: NCT0529373Accessed June 6, 2012
   Google Scholar
• Merck BMD efficacy and safety of odanacatib in postmenopausal women (0822-031)ClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2008 [updated May 14, 2012]. Available from: clinicaltrials.gov/ct2/show/NCT0729183. NLM identifier: NCT0729183Accessed June 6, 2012
   Google Scholar
• Merck A study to assess safety and efficacy of odanacatib (MK-0822) in men with osteoporosis (MK-0822-053 AM1)ClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2010 [updated July 14, 2011]. Available from: clinicaltrials.gov/ct2/show/NCT1120600. NLM identifier: NCT1120600Accessed June 6, 2012
   Google Scholar